Whanin Pharm Capital Reinvestment Ratio
Whanin Pharm capital reinvestment ratio. Whanin Pharm (016580) has a Capital Reinvestment Ratio of 0.11x as of June 2026, meaning it reinvests 0% of its operating cash flow (₩9.26 Billion) in capital expenditures (₩1.01 Billion). See Whanin Pharm free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of Whanin Pharm (2009–2025)
Capital reinvestment ratio of Whanin Pharm from 2009 to 2025. This chart tracks Whanin Pharm's Capital Reinvestment Ratio across 14 annual periods. See financial agility of Whanin Pharm to measure the company's free cash flow as a share of total liabilities.
Whanin Pharm Capital Reinvestment Ratio by Year (2009–2025)
Whanin Pharm capital reinvestment ratio by year from 2009 to 2025. For the full cash flow conversion analysis, see 016580 cash generation efficiency.
| Year | Reinvestment Ratio | Operating CF (KRW) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.68x | ₩9.04 Billion | ₩6.18 Billion | ▼ -51.9% |
| 2024 | 1.42x | ₩20.69 Billion | ₩29.38 Billion | ▲ +4.6% |
| 2023 | 1.36x | ₩23.20 Billion | ₩31.49 Billion | ▼ -32.0% |
| 2022 | 2.00x | ₩16.85 Billion | ₩33.65 Billion | ▲ +1507.6% |
| 2021 | 0.12x | ₩35.32 Billion | ₩4.39 Billion | ▼ -64.6% |
| 2020 | 0.35x | ₩22.75 Billion | ₩7.99 Billion | ▲ +214.5% |
| 2019 | 0.11x | ₩24.73 Billion | ₩2.76 Billion | ▼ -52.5% |
| 2018 | 0.23x | ₩17.45 Billion | ₩4.10 Billion | ▼ -71.4% |
| 2017 | 0.82x | ₩23.48 Billion | ₩19.31 Billion | ▲ +118.5% |
| 2016 | 0.38x | ₩19.82 Billion | ₩7.46 Billion | ▲ +57.1% |
| 2012 | 0.24x | ₩21.11 Billion | ₩5.06 Billion | ▲ +35.2% |
| 2011 | 0.18x | ₩15.12 Billion | ₩2.68 Billion | ▲ +0.0% |
| 2010 | 0.18x | ₩15.12 Billion | ₩2.68 Billion | ▲ +51.0% |
| 2009 | 0.12x | ₩18.61 Billion | ₩2.18 Billion | — |